Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 27, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,094,000 ordinary shares of 25 pence each.
- Purchase Price: 1,254.7182 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.06% of total voting rights).
- Shares in Issue: 5,236,198,614 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,094,000 shares purchased on August 27, 2008. This action was executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008. Consequently, the number of shares in issue was updated to 5,236,198,614.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,236,198,614) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its percentage of total voting rights (9.06%).
- Note that the purchased shares were cancelled rather than held indefinitely in Treasury.